SIGILON THERAPEUTICS INC (SGTX)

US82657L2060 - Common Stock

22.47  -0.59 (-2.56%)

After market: 23 +0.53 (+2.36%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026 2027 2028
Revenue
YoY % growth
13.374M
-5.55%		9.599M
-28.23%		12.944M
34.85%		16.082M
24.24%
EBITDA
YoY % growth
-51.788M
-19.22%		-74.518M
-43.89%		-42.402M
43.10%		-33.274M
21.53%		N/AN/AN/A
EBIT
YoY % growth
-52.642M
-19.32%		-75.636M
-43.68%		-43.666M
42.27%		-33.077M
24.25%
Operating Margin
-393.61%-787.96%-337.35%-205.67%
EPS
YoY % growth
N/A-2.43-7.11
-192.59%		-9.56
-34.47%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q2 / 23 Q3 / 23 Q4 / 23
EPS
Q2Q % growth		-4.81
-993.02%
Revenue
Q2Q % growth		4.335M
50.36%
EBITDA
Q2Q % growth		N/AN/AN/A
EBIT
Q2Q % growth		-8.188M
41.66%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q1 2023
Q2Q % growth		 -2.99
-595.35%		-3.010.020.52%
Q4 2022
Q2Q % growth		 -2.73
-396.36%		-5.012.2845.53%
Q3 2022
Q2Q % growth		 -3.51
-457.14%		-5.642.1337.72%
Q2 2022
Q2Q % growth		 -0.44
32.31%		-0.440.000.26%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q1 2023
Q2Q % growth		 4.858M
53.49%		3.162M1.696M53.64%
Q4 2022
Q2Q % growth		 2.644M
32.86%		2.72M-76K-2.79%
Q3 2022
Q2Q % growth		 4.252M
118.39%		2.55M1.702M66.75%
Q2 2022
Q2Q % growth		 2.883M
6.62%		2.55M333K13.06%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0.21% -1950% -1057.2% -1057.2%
Revenue0% 37.1% 27.67% 27.67%